| Sara J. Brewer Counseling | |
|
5270 Elmburg Rd Bagdad KY 40003-8000 | |
| (502) 265-6243 | |
| Not Available |
| Full Name | Sara J. Brewer Counseling |
|---|---|
| Speciality | Social Worker |
| Location | 5270 Elmburg Rd, Bagdad, Kentucky |
| Authorized Official Name and Position | Sara Brewer (OWNER) |
| Authorized Official Contact | 5022202247 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Sara J. Brewer Counseling 5270 Elmburg Rd Bagdad KY 40003-8000 Ph: (502) 265-6243 | Sara J. Brewer Counseling 5270 Elmburg Rd Bagdad KY 40003-8000 Ph: (502) 265-6243 |
| NPI Number | 1851086276 |
|---|---|
| Provider Enumeration Date | 04/11/2023 |
| Last Update Date | 05/11/2023 |
| Certification Date | 05/11/2023 |
| Medicare PECOS PAC ID | 7810352721 |
|---|---|
| Medicare Enrollment ID | O20230428000625 |
News Archive
Stargardt disease is an inherited eye disease. Its onset is typically in adolescence and it is among the leading causes of blindness in this age group. Symptoms range from severe loss of sharp vision to almost complete loss of sight.
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the full results from their first collaborative group-sponsored randomized, double-blind, placebo-controlled Phase 2 trial showing that Nexavar(R) (sorafenib) tablets in combination with the oral chemotherapeutic agent, capecitabine, significantly extended progression-free survival in patients with advanced breast cancer.
The best thing most of us can do to fight COVID-19 is stay home, to curb the respiratory disease's spread. But anyone with a computer can pitch in more actively too: by helping scientists design drugs to combat the virus now responsible for hundreds of thousands of infections worldwide.
The outbreak of severe acute respiratory syndrome (SARS) in 2002 was a loud wake-up call for researchers studying infectious diseases.
› Verified 2 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1851086276 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | (* (Not Available)) | Primary |
| Provider Name | Sara Brewer |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1104343672 PECOS PAC ID: 6800209628 Enrollment ID: I20210114002660 |
News Archive
Stargardt disease is an inherited eye disease. Its onset is typically in adolescence and it is among the leading causes of blindness in this age group. Symptoms range from severe loss of sharp vision to almost complete loss of sight.
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the full results from their first collaborative group-sponsored randomized, double-blind, placebo-controlled Phase 2 trial showing that Nexavar(R) (sorafenib) tablets in combination with the oral chemotherapeutic agent, capecitabine, significantly extended progression-free survival in patients with advanced breast cancer.
The best thing most of us can do to fight COVID-19 is stay home, to curb the respiratory disease's spread. But anyone with a computer can pitch in more actively too: by helping scientists design drugs to combat the virus now responsible for hundreds of thousands of infections worldwide.
The outbreak of severe acute respiratory syndrome (SARS) in 2002 was a loud wake-up call for researchers studying infectious diseases.
› Verified 2 days ago
News Archive
Stargardt disease is an inherited eye disease. Its onset is typically in adolescence and it is among the leading causes of blindness in this age group. Symptoms range from severe loss of sharp vision to almost complete loss of sight.
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the full results from their first collaborative group-sponsored randomized, double-blind, placebo-controlled Phase 2 trial showing that Nexavar(R) (sorafenib) tablets in combination with the oral chemotherapeutic agent, capecitabine, significantly extended progression-free survival in patients with advanced breast cancer.
The best thing most of us can do to fight COVID-19 is stay home, to curb the respiratory disease's spread. But anyone with a computer can pitch in more actively too: by helping scientists design drugs to combat the virus now responsible for hundreds of thousands of infections worldwide.
The outbreak of severe acute respiratory syndrome (SARS) in 2002 was a loud wake-up call for researchers studying infectious diseases.
› Verified 2 days ago